FDA approves rapid diagnostic test for Ebola
The U.S. FDA approved marketing of the OraQuick Ebola Rapid Antigen diagnostic test for Ebola Virus Disease (EVD). The OraQuick Ebola Test is intended for use in patients suspected of and with symptoms consistent with EVD. It may also be used in recently deceased individuals with epidemiological risk factors suspected to have died from EVD to inform decisions on safe handling of cadavers. This test is not intended for general Ebola infection screening or testing individuals at risk of exposure. Read FDA news release.